FDA approves Amarin fish-oil-derived drug to prevent heart attacks and strokes
The FDA approval reverses decades of mixed results for fish-oil-based drugs and could result in Vascepa being prescribed to millions of patients.
The Food and Drug Administration on Friday expanded the approval of Vascepa, a fish-oil-derived medicine, to allow the drug’s maker to say it prevents heart attacks, strokes, and related health problems in people who are at high cardiovascular risk.
The approval reverses decades of mixed results for fish-oil-based drugs and could result in Vascepa being prescribed to millions of patients, potentially resulting in a windfall for the drug’s maker, Amarin
